CN116964035A - 利用新型乳清酸盐中间体的肉碱乳清酸盐的制备方法 - Google Patents
利用新型乳清酸盐中间体的肉碱乳清酸盐的制备方法 Download PDFInfo
- Publication number
- CN116964035A CN116964035A CN202280018800.9A CN202280018800A CN116964035A CN 116964035 A CN116964035 A CN 116964035A CN 202280018800 A CN202280018800 A CN 202280018800A CN 116964035 A CN116964035 A CN 116964035A
- Authority
- CN
- China
- Prior art keywords
- carnitine
- orotate
- tertiary amine
- orotic acid
- carnitine orotate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- PXQPEWDEAKTCGB-UHFFFAOYSA-N orotic acid Chemical compound OC(=O)C1=CC(=O)NC(=O)N1 PXQPEWDEAKTCGB-UHFFFAOYSA-N 0.000 title claims abstract description 111
- VOTPLFCPIRIALF-UHFFFAOYSA-N 3-(2,4-dioxo-1h-pyrimidine-6-carbonyl)oxy-4-(trimethylazaniumyl)butanoate Chemical compound C[N+](C)(C)CC(CC([O-])=O)OC(=O)C1=CC(=O)NC(=O)N1 VOTPLFCPIRIALF-UHFFFAOYSA-N 0.000 title claims abstract description 58
- 238000000034 method Methods 0.000 title claims abstract description 24
- 229960005010 orotic acid Drugs 0.000 claims abstract description 51
- -1 tertiary amine salt Chemical class 0.000 claims abstract description 26
- 239000007810 chemical reaction solvent Substances 0.000 claims abstract description 15
- 150000003512 tertiary amines Chemical class 0.000 claims abstract description 15
- JXXCENBLGFBQJM-FYZOBXCZSA-N [(2r)-3-carboxy-2-hydroxypropyl]-trimethylazanium;chloride Chemical compound [Cl-].C[N+](C)(C)C[C@H](O)CC(O)=O JXXCENBLGFBQJM-FYZOBXCZSA-N 0.000 claims abstract 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 33
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 29
- 239000000126 substance Substances 0.000 claims description 13
- 238000004458 analytical method Methods 0.000 claims description 9
- 238000000634 powder X-ray diffraction Methods 0.000 claims description 8
- 238000002360 preparation method Methods 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 229910002483 Cu Ka Inorganic materials 0.000 claims description 4
- 238000000113 differential scanning calorimetry Methods 0.000 claims description 4
- 230000005855 radiation Effects 0.000 claims description 4
- PAMIQIKDUOTOBW-UHFFFAOYSA-N 1-methylpiperidine Chemical compound CN1CCCCC1 PAMIQIKDUOTOBW-UHFFFAOYSA-N 0.000 claims description 2
- HTLZVHNRZJPSMI-UHFFFAOYSA-N N-ethylpiperidine Chemical compound CCN1CCCCC1 HTLZVHNRZJPSMI-UHFFFAOYSA-N 0.000 claims description 2
- IMFACGCPASFAPR-UHFFFAOYSA-N tributylamine Chemical compound CCCCN(CCCC)CCCC IMFACGCPASFAPR-UHFFFAOYSA-N 0.000 claims description 2
- YFTHZRPMJXBUME-UHFFFAOYSA-N tripropylamine Chemical compound CCCN(CCC)CCC YFTHZRPMJXBUME-UHFFFAOYSA-N 0.000 claims description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 14
- 239000008213 purified water Substances 0.000 abstract description 13
- 239000012535 impurity Substances 0.000 abstract description 12
- 238000006243 chemical reaction Methods 0.000 abstract description 11
- 239000003960 organic solvent Substances 0.000 abstract description 9
- 238000002425 crystallisation Methods 0.000 abstract description 5
- 230000008025 crystallization Effects 0.000 abstract description 5
- 239000002904 solvent Substances 0.000 abstract description 5
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 description 29
- 229960004203 carnitine Drugs 0.000 description 13
- 239000013078 crystal Substances 0.000 description 8
- 230000000052 comparative effect Effects 0.000 description 7
- 239000002253 acid Substances 0.000 description 5
- 239000003814 drug Substances 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 208000019423 liver disease Diseases 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- ILWRPSCZWQJDMK-UHFFFAOYSA-N triethylazanium;chloride Chemical compound Cl.CCN(CC)CC ILWRPSCZWQJDMK-UHFFFAOYSA-N 0.000 description 3
- DHMOBVVEHRKNIO-UHFFFAOYSA-N 2-oxo-2-[(2-oxo-6,7,8,8a-tetrahydro-1h-acenaphthylen-3-yl)amino]acetic acid Chemical compound C1CCC2CC(=O)C3=C2C1=CC=C3NC(=O)C(=O)O DHMOBVVEHRKNIO-UHFFFAOYSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 206010058892 Carnitine deficiency Diseases 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 210000003470 mitochondria Anatomy 0.000 description 2
- XTEGVFVZDVNBPF-UHFFFAOYSA-L naphthalene-1,5-disulfonate(2-) Chemical compound C1=CC=C2C(S(=O)(=O)[O-])=CC=CC2=C1S([O-])(=O)=O XTEGVFVZDVNBPF-UHFFFAOYSA-L 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 229940127557 pharmaceutical product Drugs 0.000 description 2
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 2
- 230000001376 precipitating effect Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000007670 refining Methods 0.000 description 2
- 159000000000 sodium salts Chemical class 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 208000016505 systemic primary carnitine deficiency disease Diseases 0.000 description 2
- RPAJSBKBKSSMLJ-DFWYDOINSA-N (2s)-2-aminopentanedioic acid;hydrochloride Chemical class Cl.OC(=O)[C@@H](N)CCC(O)=O RPAJSBKBKSSMLJ-DFWYDOINSA-N 0.000 description 1
- JXXCENBLGFBQJM-UHFFFAOYSA-N (3-carboxy-2-hydroxypropyl)-trimethylazanium;chloride Chemical compound [Cl-].C[N+](C)(C)CC(O)CC(O)=O JXXCENBLGFBQJM-UHFFFAOYSA-N 0.000 description 1
- 108010082126 Alanine transaminase Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- 102000003929 Transaminases Human genes 0.000 description 1
- 239000005862 Whey Substances 0.000 description 1
- 102000007544 Whey Proteins Human genes 0.000 description 1
- 108010046377 Whey Proteins Proteins 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 238000006757 chemical reactions by type Methods 0.000 description 1
- 238000005660 chlorination reaction Methods 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 208000028208 end stage renal disease Diseases 0.000 description 1
- 201000000523 end stage renal failure Diseases 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 238000001631 haemodialysis Methods 0.000 description 1
- 230000000322 hemodialysis Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 229960001518 levocarnitine Drugs 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 210000001700 mitochondrial membrane Anatomy 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 150000004045 organic chlorine compounds Chemical class 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 229940046001 vitamin b complex Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
- C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
- C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020210028782A KR102552918B1 (ko) | 2021-03-04 | 2021-03-04 | 신규한 오르트산염 중간체를 이용한 카르니틴 오르트산염의 제조방법 |
| KR10-2021-0028782 | 2021-03-04 | ||
| PCT/KR2022/002988 WO2022186617A1 (ko) | 2021-03-04 | 2022-03-03 | 신규한 오르트산염 중간체를 이용한 카르니틴 오르트산염의 제조방법 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN116964035A true CN116964035A (zh) | 2023-10-27 |
Family
ID=83155501
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202280018800.9A Pending CN116964035A (zh) | 2021-03-04 | 2022-03-03 | 利用新型乳清酸盐中间体的肉碱乳清酸盐的制备方法 |
Country Status (4)
| Country | Link |
|---|---|
| JP (1) | JP2024511286A (ja) |
| KR (1) | KR102552918B1 (ja) |
| CN (1) | CN116964035A (ja) |
| WO (1) | WO2022186617A1 (ja) |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS375199B1 (ja) * | 1959-12-28 | 1962-06-19 | ||
| RU2084441C1 (ru) * | 1993-06-18 | 1997-07-20 | Всероссийский научный центр по безопасности биологически активных веществ | Способ получения кислотно-аддитивных солей труднорастворимых карбоновых кислот и аминов или аминокислот |
| KR101636946B1 (ko) * | 2013-07-29 | 2016-07-06 | 한국생명공학연구원 | 오로트산을 포함하는 근력약화 관련 질환의 예방 또는 치료용 약학적 조성물 |
| CN106045919B (zh) * | 2016-07-07 | 2022-08-09 | 湖北楚维药业有限公司 | 一种左旋肉碱乳清酸盐的制备方法 |
| KR20190017310A (ko) * | 2017-08-10 | 2019-02-20 | 주식회사 셀트리온화학연구소 | 약제학적 성질이 개선된 l-카르니틴 화합물의 염, 이의 제조방법, 이를 함유하는 약학 조성물 |
-
2021
- 2021-03-04 KR KR1020210028782A patent/KR102552918B1/ko active IP Right Grant
-
2022
- 2022-03-03 CN CN202280018800.9A patent/CN116964035A/zh active Pending
- 2022-03-03 JP JP2023553239A patent/JP2024511286A/ja active Pending
- 2022-03-03 WO PCT/KR2022/002988 patent/WO2022186617A1/ko active Application Filing
Also Published As
| Publication number | Publication date |
|---|---|
| WO2022186617A1 (ko) | 2022-09-09 |
| KR102552918B1 (ko) | 2023-07-10 |
| JP2024511286A (ja) | 2024-03-13 |
| KR20220125856A (ko) | 2022-09-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0150688B1 (en) | Salts of l-carnitine and alkanoyl l-carnitines and process for preparing same | |
| JP3023919B2 (ja) | Ｌ―カルニチン―マグネシウム―クエン酸塩 | |
| US20070191481A1 (en) | Sulphonic acid salt of sibutramine | |
| US20180282252A1 (en) | Method for producing optically active 2-(2-fluorobiphenyl-4-yl) propanoic acid | |
| CN116964035A (zh) | 利用新型乳清酸盐中间体的肉碱乳清酸盐的制备方法 | |
| JP2011088912A (ja) | チオクト酸のｌ−カルニチンとの塩基性塩を含む、医薬組成物および健康補助食品 | |
| EP1453791B1 (en) | Acetyl l-carnitine salt with a dicarboxilic organic acid and process for preparing same | |
| KR20040043171A (ko) | Ｒ-티옥트산의 트로메타몰 염의 신규한 개질체 및 이의제조방법 | |
| JP3125101B2 (ja) | 光学異性ヒダントインの分割方法 | |
| US7109373B2 (en) | Creatine salts and method of making same | |
| US7301051B2 (en) | Creatine salts and method of making same | |
| JPS6320817B2 (ja) | ||
| US11787808B2 (en) | Folate salts | |
| IE62410B1 (en) | Process for the resolution of threo-3-[(2-aminophenyl)-thio]-2-hydroxy-3-(4-Methoxy- phenyl) propionic acid | |
| US8940929B2 (en) | Preparation method of high-optical purity N2-[1 -(S)-ethoxycarbonyl-3-phenylpropyl]-N6-trifluoroacetyl-L-lysine | |
| SK287134B6 (sk) | Spôsob prípravy (R)- a (S)-karnitínu a medziprodukty na ich prípravu | |
| HU179780B (en) | Process for preparing thiazolidine-carboxylic acid derivatives | |
| KR20160116463A (ko) | L-α-글리세릴 포스포릴 콜린의 III형 결정 및 그 제조방법 | |
| JPS59155315A (ja) | イミダゾ−ル誘導体 | |
| JPH03287567A (ja) | 光学活性四級アンモニウム塩の製造法 | |
| CN111777507A (zh) | 丙戊酸钠的新晶型及其制备方法 | |
| KR20010071720A (ko) | Ｌ-카르니틴 및 알카노일 ｌ-카르니틴의 비-흡습성 염을함유하는 경구 투여에 적합한 고형 조성물 | |
| JP2020519624A (ja) | Ｌ−オルニチンフェニルアセテートを製造する方法 | |
| EP1852416A1 (en) | Enantiomeric resolution of a carnitinamide salt by preferential crystallization | |
| FR2896801A1 (fr) | Nouveaux composes dipeptidiques, les compositions pharmaceutiques en renfermant ainsi que leur procede d'obtention |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |